Search
Use the filters to narrow by type of content
Looking for a Publication? Search the bibliography for: sites default files Rare Disease Webinar Slides Final Feb 27 pdf
… Lung Cancer with Capmatinib Share on: February 27, 2023 Non-small cell lung cancer (NSCLC) is an aggressive disease, with poor prognosis and a high likelihood of brain … real-world clinical outcomes in patients with NSCLC with a rare MET exon 14 skipping mutation and brain metastases …
… Literature reviews can be stand-alone projects such as a disease (including rare disease) or regulatory landscape analysis. Alternatively, …
40th Annual Meeting of the European Society for Paediatric Infectious Diseases (ESPID) Share on: Monday, May 9 - Friday, May 13, 2022 Conference Website Research coauthored by RTI Health Solutions researchers will be presented at the 40th Annual Meeting …
… of Inclusive Language in Medical Writing Share on: May 27, 2022 One of the cultural pillars at RTI Health Solutions …
… device, vaccine, and other treatment safety profiles Disease prevalence and public health impact Event rates … of electronic database information to identify specific disease endpoints Our experts have conducted database … Friuli-Venezia Giulia, Caserta* Japan Japan Chronic Kidney Disease Database (J-CKD-DB) Netherlands PHARMO Institute …
… picture of how well childhood immunizations prevent disease and the economic impact of this disease prevention. These new studies were conducted because of changes in disease epidemiology, vaccine uptake, and evolving …
… Congress 2023 Share on: Monday, November 27 - Tuesday, November 28, 2023 Conference website Susana … the safety of medical interventions. Perez-Gutthann S. 27 November, 2023, 2:25pm Session 3 - Real World Evidence in …
… publications span many therapeutic areas, including kidney disease, cardiovascular disease, diabetes, men’s health, vaccines, and pregnancy. He …
… gene therapies), and medical technologies. Therapies for rare diseases will be introduced from January 2028 and for … more large-molecule drugs or biologicals instead. On the disease-area level, companies might be thinking of … These Challenges? We support clients on portfolio and disease-area levels as well as with individual drugs in …
… in randomized clinical trials and robust information on rare adverse events was lacking. As the availability of …